52 related articles for article (PubMed ID: 38627727)
1. An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma.
Du Z; Han X; Zhu L; Li L; Castellano L; Stebbing J; Peng L; Wang Z
BMC Med Genomics; 2024 Apr; 17(1):86. PubMed ID: 38627727
[TBL] [Abstract][Full Text] [Related]
2. Establishment and Evaluation of Exosomes-Related Gene Risk Model in Hepatocellular Carcinoma.
Zhu L; Lou Y; Xiao Q; Wang L; Chen G; Yang W; Wang T
Biochem Genet; 2024 Apr; 62(2):698-717. PubMed ID: 37405532
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
4. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
7. exoRBase 2.0: an atlas of mRNA, lncRNA and circRNA in extracellular vesicles from human biofluids.
Lai H; Li Y; Zhang H; Hu J; Liao J; Su Y; Li Q; Chen B; Li C; Wang Z; Li Y; Wang J; Meng Z; Huang Z; Huang S
Nucleic Acids Res; 2022 Jan; 50(D1):D118-D128. PubMed ID: 34918744
[TBL] [Abstract][Full Text] [Related]
8. HCC and Molecular Targeting Therapies: Back to the Future.
Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462
[TBL] [Abstract][Full Text] [Related]
9. The exosome journey: from biogenesis to uptake and intracellular signalling.
Gurung S; Perocheau D; Touramanidou L; Baruteau J
Cell Commun Signal; 2021 Apr; 19(1):47. PubMed ID: 33892745
[TBL] [Abstract][Full Text] [Related]
10. Exosome-based liquid biopsies in cancer: opportunities and challenges.
Yu W; Hurley J; Roberts D; Chakrabortty SK; Enderle D; Noerholm M; Breakefield XO; Skog JK
Ann Oncol; 2021 Apr; 32(4):466-477. PubMed ID: 33548389
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma.
Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS
Nat Rev Dis Primers; 2021 Jan; 7(1):6. PubMed ID: 33479224
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
13. Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present).
Hu S; Hui Z; Lirussi F; Garrido C; Ye XY; Xie T
Expert Opin Ther Pat; 2021 May; 31(5):435-452. PubMed ID: 33347360
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
